People · Operator
Named in public records as an officer, director or promoter · active 2010–2024 · Other Health Care, Biotechnology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Renovaro Inc. | — | Other Health Care | Series D+ | $123.3M | $1.2B | 2024 |
| Alliqua BioMedical, Inc. | — | Biotechnology | Series A | $52.6M | $100.1M | 2012 |
| First Wave BioPharma, Inc. | — | Biotechnology | Series B | $50.4M | $13.4M | 2019 |
| Hepion Pharmaceuticals, Inc. | — | Pharmaceuticals | Series B | $46.1M | $19.9M | 2014 |
| Tobira Therapeutics, Inc. | — | Biotechnology | Series A | $23.2M | $513.3M | 2010 |
| Onconetix, Inc. | — | Biotechnology | Series A | $22.0M | $37.7M | 2024 |
| Marizyme Inc | — | Biotechnology | Series A | $15.6M | $9.1M | 2020 |
James Sapirstein at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside James Sapirstein on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Carol Brosgart | 2 | 3 |
| David Johnson | 1 | 35 |
| Patrick Heron | 1 | 11 |
| Brian Halak | 1 | 10 |
| Mark Wagner | 1 | 9 |
| David Hoffman | 1 | 7 |
| Steven Berger | 1 | 7 |
| Richard Rosenblum | 1 | 6 |
| Jerome Zeldis | 1 | 6 |
| Kenneth Londoner | 1 | 5 |
| Ajit Singh | 1 | 5 |
| John Brancaccio | 1 | 5 |
| Charles Casamento | 1 | 5 |
| Laurent Fischer | 1 | 4 |
| Robert Foster | 1 | 4 |
| Daniel Turner | 1 | 4 |
| Johan (Thijs) Spoor | 1 | 4 |
| Joseph Sierchio | 1 | 3 |
| Johan M Spoor | 1 | 3 |
| Maged Shenouda | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.